Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04736472 · ClinicalTrials.gov registry record · NA
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 552
- Enrollment target
NCT04736472 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 552 participants.
The verdict
NCT04736472, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 552 participants
- Enrollment target
Study Summary
Pharmacogenomics (PGx) is the study of how genes affect a person's response to drugs. PGx testing for certain genes can help predict the risk of side effects from chemotherapy agents. Testing is not regularly performed in clinical practice due to long wait times for results and challenges with integrating test results in the electronic health record. Investigators leading this study hope to find out if providing cancer care providers with the ability to order a PGx test and electronically receive results with dosing recommendations will increase the use of these tests to guide treatment decisions and improve patient outcomes. This is a non-randomized implementation study, which means that all participants in this study will undergo genotyping for a pharmacogenetic test. The investigators will primarily measure the feasibility of using this test to guide cancer care.
Interventions
- DEVICE Pharmacogenetic test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 552 participants |
| Start Date | 2021-03-26 |
| Est. Completion | 2024-10-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04736472
The ClinicalTrials.gov registry entry for NCT04736472 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 552 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pharmacogenetic test is the first listed.
NCT04736472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04736472 about?
NCT04736472 is a clinical study titled "Implementing Pharmacogenetic Testing in Gastrointestinal Cancers". Pharmacogenomics (PGx) is the study of how genes affect a person's response to drugs. PGx testing for certain genes can help predict the risk of side effects from chemotherapy agents. Testing is not regularly performed in clinical practice due to long wait times for results and challenges with integ...
What is the current status of trial NCT04736472?
This trial is currently completed. It is a NA study. The enrollment target is 552 participants. The study started on 2021-03-26. Estimated completion is 2024-10-09.
What interventions are being tested in trial NCT04736472?
The interventions under investigation include: Pharmacogenetic test (DEVICE).
Who is sponsoring clinical trial NCT04736472?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.